Charles A. Staley
MD
Dr. Staley leads the surgical oncology team and as Chief Quality Officer works collaboratively with leadership on tracking and improving patient services and satisfaction as well as focusing on cancer outcomes at Winship.
Titles and Roles
- Chief Quality Officer
- Winship Cancer Institute of Emory University
- Chief, Division of Surgical Oncology
- Winship Cancer Institute of Emory University
- Professor, Division of Surgical Oncology, Department of Surgery
- Emory University School of Medicine
- Research Program
- Discovery and Developmental Therapeutics
Biography
Charles A. Staley, MD, specializes in the surgical treatment of stomach, esophageal, appendiceal, colorectal, pancreas, liver cancer, and peritoneal surface malignancies. Dr. Staley is the Program Director for the Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Program for patients with peritoneal cancers from gastric, colorectal, mesothelioma, and pseudomyxoma peritonei cancers. With research interests encompassing translational research and novel clinical trials in gastrointestinal cancers, he has investigated gene therapy for metastatic colon cancer, radiofrequency ablation with intra-arterial chemotherapy for patients with colorectal liver metastases, and is currently attempting to develop targeted superparamagnetic iron oxide nanoparticles for the therapy of pancreatic cancer.
Dr. Staley currently coordinates national efforts for clinical cancer research through his efforts in the Eastern Cooperative Oncology Group as one of its principle investigators for clinical trials and Chair of the Surgical Committee. He is also chair of the Vizient UHC Cancer Center Network Steering Committee which oversees the Vizient Cancer Network comprising approximately 125 cancer centers nationally. The network was created to begin a national network to share ideas about improving the quality of cancer care.
Education
After receiving his MD with honors from Dartmouth Medical School in 1987, Dr. Staley did his general surgery residency at the University Health Center of Pittsburgh and his surgical oncology fellowship at M.D. Anderson Cancer Center. Throughout his fellowship years he was recognized for his clinical and research interests in the treatment of gastrointestinal and liver cancer, winning such awards as the M.D. Anderson Clinical Fellows Research Award, a University Cancer Foundation Research Grant, a Clinical Fellowship Award from the American Cancer Society. Upon completing the fellowship in 1995, Dr. Staley was appointed Holland M. Ware Professor in Surgical Oncology and Chief of the Division of Surgical Oncology of the Department of Surgery, Emory University School of Medicine.
Research
With research interests encompassing translational research and novel clinical trials in gastrointestinal cancers, Dr. Staley has investigated gene therapy for metastatic colon cancer, radiofrequency ablation with intra-arterial chemotherapy for patients with colorectal liver metastases, and neoadjuvant chemoradiation with the goal of maximizing sphincter preservation in the treatment of rectal cancer. In the area of translational science, Dr. Staley and such colleagues as Dr. Lily Yang are exploring methods of using nanotechnology to diagnose and treat pancreatic and breast cancer.
Publications
Publications Publication Date
Awards
Dr. Staley was named as one of Atlanta Magazine's "Top Doctors" in 2015, 2016 and 2017.